Gary Brecka warns GLP-1 trials show substantial lean-mass loss
"A 2024 review published in Diabetes, Obesity and Metabolism examined lean body mass changes across GLP-1 clinical trials and found that in some studies reductions in lean mass accounted for 40 to 60% of the total weight lost. Let me say that again. 60% of the weight loss was from muscle dense tissue."
About this episode
Host Gary Brecka discusses GLP-1 weight-loss medicines (including semaglutide and tirzepatide) and argues that the public conversation focuses too narrowly on kilograms lost rather than what tissue is being lost. He outlines an overview of drug development from single-agonist GLP-1 medications to newer dual-agonist and triple-agonist candidates, citing a 2024 review in Endocrinology and Metabolism and a phase 2 retatrutide result he says produced 24.2% mean body-weight loss at 48 weeks.
Brecka’s central warning is that appetite suppression can reduce protein intake and contribute to loss of lean mass. He cites a 2024 review in Diabetes, Obesity and Metabolism which he says found that, in some studies, 40–60% of weight lost in GLP-1 trials came from lean mass. He characterises this as a “metabolic loss” that could lower resting energy expenditure, impair strength, and make it harder to maintain weight loss.
He advises that patients using GLP-1 medications should follow structured programmes emphasising resistance training and sufficient dietary protein, offering a target range of roughly 0.7–1 gram of protein per pound of body weight daily and recommending three weekly resistance-training sessions focused on compound lifts. The episode ends with a brief recommendation to watch a separate GLP-1-related interview episode with another guest.
Key takeaways
- Brecka says weight loss on GLP-1 medicines can include significant lean-mass loss, not just fat loss.
- He cites a 2024 Diabetes, Obesity and Metabolism review which he says found lean mass reductions accounted for 40–60% of total weight lost in some studies.
- He cites a 2024 Endocrinology and Metabolism review and reports a phase 2 retatrutide result of 24.2% mean weight loss at 48 weeks (12 mg dose).
- He argues newer multi-agonist drugs may be more potent, increasing the importance of protecting muscle mass.
- He recommends resistance training specifically (not just cardio) while using GLP-1 medicines.
- He gives a protein target of roughly 0.7–1g per pound of body weight daily while on GLP-1s.